keyword
MENU ▼
Read by QxMD icon Read
search

UKPDS

keyword
https://www.readbyqxmd.com/read/28776081/metformin-historical-overview
#1
EDITORIAL
Clifford J Bailey
Metformin (dimethylbiguanide) has become the preferred first-line oral blood glucose-lowering agent to manage type 2 diabetes. Its history is linked to Galega officinalis (also known as goat's rue), a traditional herbal medicine in Europe, found to be rich in guanidine, which, in 1918, was shown to lower blood glucose. Guanidine derivatives, including metformin, were synthesised and some (not metformin) were used to treat diabetes in the 1920s and 1930s but were discontinued due to toxicity and the increased availability of insulin...
August 3, 2017: Diabetologia
https://www.readbyqxmd.com/read/28770324/impact-of-metformin-on-cardiovascular-disease-a-meta-analysis-of-randomised-trials-among-people-with-type-2-diabetes
#2
REVIEW
Simon J Griffin, James K Leaver, Greg J Irving
AIMS/HYPOTHESIS: Metformin is the most-prescribed oral medication to lower blood glucose worldwide. Yet previous systematic reviews have raised doubts about its effectiveness in reducing risk of cardiovascular disease, the most costly complication of type 2 diabetes. We aimed to systematically identify and pool randomised trials reporting cardiovascular outcomes in which the effect of metformin was 'isolated' through comparison to diet, lifestyle or placebo. METHODS: We performed an electronic literature search of MEDLINE, EMBASE and the Cochrane Library...
August 2, 2017: Diabetologia
https://www.readbyqxmd.com/read/28680124/refining-long-term-prediction-of-cardiovascular-risk-in-diabetes-the-vildia-score
#3
Georg Goliasch, Günther Silbernagel, Marcus E Kleber, Tanja B Grammer, Stefan Pilz, Andreas Tomaschitz, Philipp E Bartko, Gerald Maurer, Wolfgang Koenig, Alexander Niessner, Winfried März
Cardiovascular risk assessment in patients with diabetes relies on traditional risk factors. However, numerous novel biomarkers have been found to be independent predictors of cardiovascular disease, which might significantly improve risk prediction in diabetic patients. We aimed to improve prediction of cardiovascular risk in diabetic patients by investigating 135 evolving biomarkers. Based on selected biomarkers a clinically applicable prediction algorithm for long-term cardiovascular mortality was designed...
July 5, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28607554/lower-extremity-peripheral-arterial-disease-is-an-independent-predictor-of-coronary-heart-disease-and-stroke-risks-in-patients-with-type-2-diabetes-mellitus-in-china
#4
Xiao-Hong Pang, Jue Han, Wan-Lan Ye, Xue Sun, Yue Ding, Wen-Juan Huang, Yi-Ming Zhao, Han-Yu Lou, Li-Zhen Shan, Ying-Xiu Kang, Xiao-Xiao Song, Song-Zhao Zhang, Wei Gu, Peng-Fei Shan
We aimed to determine the relationship between lower extremity peripheral arterial disease (PAD), 10-year coronary heart disease (CHD), and stroke risks in patients with type 2 diabetes (T2DM) using the UKPDS risk engine. We enrolled 1178 hospitalized T2DM patients. The patients were divided into a lower extremity PAD group (ankle-brachial index ≤ 0.9 or >1.4; 88 patients, 7.5%) and a non-PAD group (ankle-brachial index > 0.9 and ≤1.4; 1090 patients, 92.5%). Age; duration of diabetes; systolic blood pressure; the hypertension rate; the use of hypertension drugs, ACEI /ARB, statins; CHD risk; fatal CHD risk; stroke risk; and fatal stroke risk were significantly higher in the PAD group than in the non-PAD group (P < 0...
2017: International Journal of Endocrinology
https://www.readbyqxmd.com/read/28522196/impact-of-glucose-lowering-therapies-on-risk-of-stroke-in-type-2-diabetes
#5
REVIEW
F Bonnet, A J Scheen
Patients with type 2 diabetes (T2D) have an increased risk of stroke compared with people without diabetes. However, the effects of glucose-lowering drugs on risk of ischaemic stroke in T2D have been less extensively investigated than in coronary heart disease. Some evidence, including the UKPDS, has suggested a reduced risk of stroke with metformin, although the number of studies is limited. Inhibition of the KATP channels increases ischaemic brain lesions in animals. This is in agreement with a recent meta-analysis showing an increased risk of stroke with sulphonylureas vs...
May 15, 2017: Diabetes & Metabolism
https://www.readbyqxmd.com/read/28369151/type-1-diabetes-developing-the-first-risk-estimation-model-for-predicting-silent-myocardial-ischemia-the-potential-role-of-insulin-resistance
#6
Gemma Llauradó, Albert Cano, Cristina Hernández, Montserrat González-Sastre, Ato-Antonio Rodríguez, Jordi Puntí, Eugenio Berlanga, Lara Albert, Rafael Simó, Joan Vendrell, José-Miguel González Clemente
OBJECTIVES: The aim of the study was to develop a novel risk estimation model for predicting silent myocardial ischemia (SMI) in patients with type 1 diabetes (T1DM) and no clinical cardiovascular disease, evaluating the potential role of insulin resistance in such a model. Additionally, the accuracy of this model was compared with currently available models for predicting clinical coronary artery disease (CAD) in general and diabetic populations. RESEARCH, DESIGN AND METHODS: Patients with T1DM (35-65years, >10-year duration) and no clinical cardiovascular disease were consecutively evaluated for: 1) clinical and anthropometric data (including classical cardiovascular risk factors), 2) insulin sensitivity (estimate of glucose disposal rate (eGDR)), and 3) SMI diagnosed by stress myocardial perfusion gated SPECTs...
2017: PloS One
https://www.readbyqxmd.com/read/28365411/effects-of-intensive-glucose-control-on-microvascular-outcomes-in-patients-with-type-2-diabetes-a-meta-analysis-of-individual-participant-data-from-randomised-controlled-trials
#7
Sophia Zoungas, Hisatomi Arima, Hertzel C Gerstein, Rury R Holman, Mark Woodward, Peter Reaven, Rodney A Hayward, Timothy Craven, Ruth L Coleman, John Chalmers
BACKGROUND: Intensive glucose control is understood to prevent complications in adults with type 2 diabetes. We aimed to more precisely estimate the effects of more intensive glucose control, compared with less intensive glucose control, on the risk of microvascular events. METHODS: In this meta-analysis, we obtained de-identified individual participant data from large-scale randomised controlled trials assessing the effects of more intensive glucose control versus less intensive glucose control in adults with type 2 diabetes, with at least 1000 patient-years of follow-up in each treatment group and a minimum of 2 years average follow-up on randomised treatment...
June 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/28225988/estimation-of-cardiovascular-risk-and-detection-of-subclinical-carotid-atheromatosis-in-patients-with-diabetes-without-a-history-of-cardiovascular-disease
#8
Walter Masson, Salvador De Francesca, Micaela Molinero, Daniel Siniawski, Andrés Mulassi, Frank Espinoza Morales, Melina Huerin, Martín Lobo, Graciela Molinero
Objectives: Cardiovascular risk estimated by several scores in patients with diabetes mellitus without a cardiovascular disease history and the association with carotid atherosclerotic plaque (CAP) were the aims of this study. Materials and methods: Cardiovascular risk was calculate using United Kingdom Prospective Diabetes Study (UKPDS) risk engine, Framingham risk score for cardiovascular (FSCV) and coronary disease (FSCD), and the new score (NS) proposed by the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol...
March 2017: Archives of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28197833/auxiliendo-primum-non-nocere-a-preliminary-view-of-the-devote-trial-comparing-cardiovascular-safety-of-insulin-degludec-versus-insulin-glargine-in-type-2-diabetes
#9
Sanjay Kalra
A demonstration of cardiovascular safety is mandatory for all newly developed glucose-lowering agents, including insulin analogues. The vascular benefit of insulin is evident from the Diabetes Control and Complication Trial (DCCT) and United Kingdom Prospective Diabetes Study (UKPDS), and the cardiovascular safety of insulin glargine has been demonstrated in individuals with newly diagnosed diabetes or prediabetes in the ORIGIN trial (Outcome Reduction with an Initial Glargine Intervention). The top-line results of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs...
April 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28056470/-anti-diabetic-medication-during-the-first-four-years-of-treatment-a-study-based-on-claims-data
#10
Veronika Lappe, Ingrid Köster, Ingrid Schubert
Background Ever since the UKPDS study reassessed the usefulness of the substance metformin in 1998, it has been the first-line medication in anti-diabetic treatment. In addition, new classes and agents released on the market have given rise to new treatment options. The present study investigates prescription practice at the onset of treatment and in the years thereafter and measures it against German diabetes guidelines. Database and Methods Database: Statutory health insurance sample AOK/KV Hesse; Ages: 40 and over (N = 142514)...
January 2017: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/28026908/an-alternative-approach-to-modelling-hba1c-trajectories-in-patients-with-type-2-diabetes-mellitus
#11
Phil McEwan, Hayley Bennett, Lei Qin, Klas Bergenheim, Jason Gordon, Marc Evans
AIMS: Time-dependent HbA1c trajectories in health economic models of type 2 diabetes mellitus (T2DM) are typically informed by the UK Prospective Diabetes Study (UKPDS). However, this approach may not accurately predict HbA1c progression in patients who do not conform to the demographic profile of the original UKPDS cohort. This study aimed to develop an alternative mathematical model (MM) to simulate HbA1c progression in T2DM. MATERIALS AND METHODS: A systematic literature review identified studies, published between 2005 and 2015, that reported HbA1c in adult T2DM patients over a minimum duration of 18 months...
May 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28024655/prevalence-by-computed-tomographic-angiography-of-coronary-plaques-in-south-asian-and-white-patients-with-type-2-diabetes-mellitus-at-low-and-high-risk-using-four-cardiovascular-risk-scores-ukpds-frs-ascvd-and-jbs3
#12
Sanjay N Gobardhan, Aukelien C Dimitriu-Leen, Alexander R van Rosendael, Erik W van Zwet, Cornelis J Roos, Pranobe V Oemrawsingh, Aan V Kharagjitsingh, J Wouter Jukema, Victoria Delgado, Martin J Schalij, Jeroen J Bax, Arthur J H A Scholte
The aim of this study was to explore the association between various cardiovascular (CV) risk scores and coronary atherosclerotic burden on coronary computed tomography angiography (CTA) in South Asians with type 2 diabetes mellitus and matched whites. Asymptomatic type 2 diabetic South Asians and whites were matched for age, gender, body mass index, hypertension, and hypercholesterolemia. Ten-year CV risk was estimated using different risk scores (United Kingdom Prospective Diabetes Study [UKPDS], Framingham Risk Score [FRS], AtheroSclerotic CardioVascular Disease [ASCVD], and Joint British Societies for the prevention of CVD [JBS3]) and categorized into low- and high-risk groups...
March 1, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/28002036/serum-levels-of-oxidative-stress-markers-in-patients-with-type-2-diabetes-mellitus-and-non-alcoholic-steatohepatitis
#13
F Casoinic, D Sampelean, Anca D Buzoianu, N Hancu, Dorina Baston
INTRODUCTION: Oxidative stress is one of the key mechanisms responsible for disease progression in non-alcoholic fatty liver disease. The aim of this study was to evaluate the serum levels of oxidative stress markers in patients with type 2 diabetes mellitus (DMT2) and non-alcoholic steatohepatitis (NASH) and test their relationships with clinical and biochemical patient characteristics, compared to patients with DMT2 without non-alcoholic fatty liver disease (NAFLD), and controls. MATERIALS AND METHODS: In all, 60 consecutive patients with DMT2 and NASH, 55 with DMT2 without NAFLD, and 50 age-and-gender-matched healthy subjects participated in the study...
December 1, 2016: Romanian Journal of Internal Medicine, Revue Roumaine de Médecine Interne
https://www.readbyqxmd.com/read/27957711/the-role-of-beta-blockers-in-the-treatment-of-hypertension
#14
John M Cruickshank
IMPORTANCE: Two major guide-line committees (JNC-8 and NICE UK) have dropped beta-blockers as first-line therapy in the treatment of hypertension. Also, recent meta-analyses (that do not take age into account) have concluded that beta-blockers are inappropriate first-line agents in the treatment of hypertension. This review seeks to shed some light on the "rights and wrongs" of such actions and conclusions. OBJECTIVES: Because the pathophysiology of primary/essential hypertension differs in elderly and younger subjects, the latter being closely linked to obesity and increased sympathetic nerve activity, the author sought to clarify the efficacy of beta-blockers in the younger/middle-aged group in reducing the risk of death, and cardiovascular end-points...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/27774422/complementary-and-alternative-medicine-in-indian-parkinson-s-disease-patients
#15
Awadh Kishor Pandit, Deepti Vibha, Achal Kumar Srivastava, Garima Shukla, Vinay Goyal, Madhuri Behari
Use of complementary and alternative medicine (CAM; bǔ chōng yǔ tì dài yī xué) in Parkinson disease (PD) ranged 40-70%. The objective of this study was to determine the frequency, types and factors associated with the use of CAM in Indian PD patients. PD patients, fulfilling UKPD-Society brain-bank diagnostic-criteria, attending Movement-disorders clinic of a tertiary-care teaching hospital in India from 1st May to 15th December 2012 were enrolled. Information on socio-demographic, clinical data and treatment along with factors (source of information, benefits, harms, reason for use and cost) associated with CAM use were recorded...
October 2016: Journal of Traditional and Complementary Medicine
https://www.readbyqxmd.com/read/27749939/quality-of-diabetes-care-in-germany-improved-from-2000-to-2007-to-2014-but-improvements-diminished-since-2007-evidence-from-the-population-based-kora-studies
#16
Michael Laxy, Gabriella Knoll, Michaela Schunk, Christa Meisinger, Cornelia Huth, Rolf Holle
OBJECTIVE: Little is known about the development of the quality of diabetes care in Germany. The aim of this study is to analyze time trends in patient self-management, physician-delivered care, medication, risk factor control, complications and quality of life from 2000 to 2014. METHODS: Analyses are based on data from individuals with type 2 diabetes of the population-based KORA S4 (1999-2001, n = 150), F4 (2006-2008, n = 203), FF4 (2013/14, n = 212) cohort study...
2016: PloS One
https://www.readbyqxmd.com/read/27727281/delivering-diabetes-education-through-nurse-led-telecoaching-cost-effectiveness-analysis
#17
RANDOMIZED CONTROLLED TRIAL
Irina Odnoletkova, Dirk Ramaekers, Frank Nobels, Geert Goderis, Bert Aertgeerts, Lieven Annemans
BACKGROUND: People with diabetes have a high risk of developing micro- and macrovascular complications associated with diminished life expectancy and elevated treatment costs. Patient education programs can improve diabetes control in the short term, but their cost-effectiveness is uncertain. Our study aimed to analyze the lifelong cost-effectiveness of a nurse-led telecoaching program compared to usual care in people with type 2 diabetes from the perspective of the Belgian healthcare system...
2016: PloS One
https://www.readbyqxmd.com/read/27716211/a-19-snp-coronary-heart-disease-gene-score-profile-in-subjects-with-type-2-diabetes-the-coronary-heart-disease-risk-in-type-2-diabetes-cordia-study-study-baseline-characteristics
#18
RANDOMIZED CONTROLLED TRIAL
Katherine E Beaney, Claire E Ward, Dauda A S Bappa, Nadine McGale, Anna K Davies, Shashivadan P Hirani, KaWah Li, Philip Howard, Dwaine R Vance, Martin A Crockard, John V Lamont, Stanton Newman, Steve E Humphries
BACKGROUND: The coronary risk in diabetes (CoRDia) trial (n = 211) compares the effectiveness of usual diabetes care with a self-management intervention (SMI), with and without personalised risk information (including genetics), on clinical and behavioural outcomes. Here we present an assessment of randomisation, the cardiac risk genotyping assay, and the genetic characteristics of the recruits. METHODS: Ten-year coronary heart disease (CHD) risk was calculated using the UKPDS score...
October 3, 2016: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/27678079/the-cost-effectiveness-of-hospital-based-telephone-coaching-for-people-with-type-2-diabetes-a-10%C3%A2-year-modelling-analysis
#19
J E Varney, D Liew, T J Weiland, W J Inder, G A Jelinek
BACKGROUND: Type 2 diabetes (T2DM) is a burdensome condition for individuals to live with and an increasingly costly condition for health services to treat. Cost-effective treatment strategies are required to delay the onset and slow the progression of diabetes related complications. The Diabetes Telephone Coaching Study (DTCS) demonstrated that telephone coaching is an intervention that may improve the risk factor status and diabetes management practices of people with T2DM. Measuring the cost effectiveness of this intervention is important to inform funding decisions that may facilitate the translation of this research into clinical practice...
September 27, 2016: BMC Health Services Research
https://www.readbyqxmd.com/read/27630880/association-of-risk-estimates-of-three-different-cardiovascular-risk-assessment-tools-with-carotid-intima-media-thickness-in-patients-with-type-2-diabetes
#20
Herath Mudiyanselage Meththananda Herath, Thilak Priyantha Weerarathna, Ranasinghe Bethmi Arachige Thilini Dulanjalee, Madumekala Rupasinghe Jayawardana, Udara Priyadarshani Edirisingha, Madushanka Rathnayake
INTRODUCTION: Risk assessment tools used to calculate the Cardiovascular Disease (CVD) risk such as the Framingham Risk Score (FRS), United Kingdom Prospective Diabetes study (UKPDS) risk engine and the World Health Organization (WHO) risk score have not been tested on their ability to detect subclinical atherosclerosis in most developing countries. AIM: To study the association between the calculated CVD risk scores using each of these tools and Carotid Intima Medial Thickness (CIMT), a surrogate marker of atherosclerosis, in a group of patients with Type 2 diabetes (T2DM) in Sri Lanka...
July 2016: Journal of Clinical and Diagnostic Research: JCDR
keyword
keyword
41191
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"